LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

BACKGROUND: SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and is administered intramuscularly monthly or every 2 months by a healthcare provider. COVID-19 and the resultant restrictio...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Amico, Ronald, Benn, Paul, McCoig, Cynthia C, Griffith, Sandy, Hudson, Krischan J, Sutton, Kenneth, Harrington, Conn M, Wu, Sterling, Williams, Will, Hove, Kai S, Martin Espanol, Carlos, Fricker, E Jane, Patel, Parul, Margolis, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777408/
http://dx.doi.org/10.1093/ofid/ofaa515.1905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777408/
http://dx.doi.org/10.1093/ofid/ofaa515.1905

Ejemplares similares